Comparative proteogenomic characterization of glioblastoma.

Glioblastoma multiforme (GBM) carries a dismal prognosis. Integrated proteogenomic analysis was performed to understand GBM pathophysiology.  17 patient samples were analyzed for driver mutations, oncogenes, major pathway alterations and molecular changes at gene and protein level. Clinical, treatment and survival data were collected. Significantly mutated genes included , , , , , and . EGFR mutations noted included EGFRvIII-expression, EGFR- missense mutation-exon 21 and EGFR fusion (FGFR3-TACC3). mutations were noticed in COSMIC hot-spot driver gene and accompany and mutations suggesting low- to high-grade glioma transformation. Proteomics showed higher (53%) EGFR expression than genomic expression (23%). MGMT methylation was present in two-thirds of cases. This study identifies a distinct biological process that may characterize each GBM differently. Proteogenomic data identify potential therapeutic targets of GBM.